Tiziana Life Sciences Ltd (NASDAQ:TLSA – Get Free Report)’s share price was up 1.1% during trading on Monday. The stock traded as high as $0.6107 and last traded at $0.5762. 665,310 shares traded hands during trading, an increase of 23% from the average session volume of 541,569 shares. The stock had previously closed at $0.5699.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on TLSA shares. Weiss Ratings raised Tiziana Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, October 19th. Wall Street Zen raised shares of Tiziana Life Sciences from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 24th. Finally, BTIG Research reissued a “buy” rating on shares of Tiziana Life Sciences in a research note on Tuesday, September 22nd. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold”.
View Our Latest Stock Analysis on Tiziana Life Sciences
Tiziana Life Sciences Price Performance
The stock’s 50-day moving average is $0.92 and its 200 day moving average is $1.16.
Hedge Funds Weigh In On Tiziana Life Sciences
Large investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Tiziana Life Sciences by 177.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 50,000 shares of the company’s stock valued at $56,000 after buying an additional 32,000 shares during the period. Zhang Financial LLC boosted its stake in shares of Tiziana Life Sciences by 12.0% in the first quarter. Zhang Financial LLC now owns 111,900 shares of the company’s stock valued at $131,000 after buying an additional 12,000 shares in the last quarter. Mid American Wealth Advisory Group Inc. purchased a new stake in shares of Tiziana Life Sciences in the second quarter valued at approximately $414,000. Finally, Marshall Wace LLP acquired a new position in Tiziana Life Sciences during the third quarter worth $1,315,000.
About Tiziana Life Sciences
Tiziana Life Sciences is a biotechnology company developing treatments for inflammatory and neurodegenerative diseases. Its development work has focused on foralumab, a fully human monoclonal antibody that targets CD3, a protein found on T cells involved in the immune response. The company is investigating an intranasal formulation of foralumab for conditions including non-active secondary progressive multiple sclerosis and Alzheimer’s disease. These uses remain investigational, and foralumab is not an approved treatment.
Further Reading
- Five stocks we like better than Tiziana Life Sciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
